Immunicum AB (SE:IMMU)
:IMMU
Top Page
Immunicum AB
(IMMU)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr5.00
▼(-13.34% Downside)
Action:ReiteratedDate:03/27/26
The score is held down mainly by weak financial performance (ongoing losses, zero recent revenue, and continued cash burn) and soft technical conditions (below key longer-term moving averages with negative MACD). Valuation is not a clear support due to negative earnings and no dividend yield provided.
Positive Factors
Balance Sheet Strength
Low reported leverage and a meaningful equity base provide durable financial flexibility for a pre-revenue biotech. That stronger balance sheet relative to peers supports continued R&D spending, partnership negotiations, or bridge financing without immediate solvency risk.
Negative Factors
Persistent Losses & Zero Revenue
Zero recent revenue combined with ongoing operating losses means the company lacks commercial cash inflows to fund operations. Over the medium term this forces reliance on external funding and indicates the business has not achieved durable commercial traction.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Low reported leverage and a meaningful equity base provide durable financial flexibility for a pre-revenue biotech. That stronger balance sheet relative to peers supports continued R&D spending, partnership negotiations, or bridge financing without immediate solvency risk.
Read all positive factors
Immunicum AB (IMMU) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr271.88M
Dividend YieldN/A
Average Volume (3M)38.75K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue GrowthN/A
EPS Growth31.37%
CountrySE
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding62,584,580
10 Day Avg. Volume52,324
30 Day Avg. Volume38,751
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.69
Revenue Forecast (FY)kr5.00M
Immunicum AB Business Overview & Revenue Model
Company Description
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/I...
How the Company Makes Money
null...
Immunicum AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 28.49M | 3.00M | 6.00K |
| Gross Profit | 0.00 | -6.52M | 28.49M | -1.85M | -1.84M |
| EBITDA | -120.26M | -120.66M | -97.85M | -128.67M | -128.28M |
| Net Income | -113.26M | -128.40M | -101.62M | -136.99M | -136.69M |
Balance Sheet | |||||
| Total Assets | 628.32M | 696.36M | 755.95M | 620.39M | 720.98M |
| Cash, Cash Equivalents and Short-Term Investments | 64.66M | 101.91M | 120.78M | 41.85M | 155.31M |
| Total Debt | 33.28M | 22.71M | 24.49M | 78.16M | 36.98M |
| Total Liabilities | 43.26M | 51.22M | 51.23M | 105.95M | 64.24M |
| Stockholders Equity | 585.07M | 645.15M | 704.73M | 514.44M | 656.74M |
Cash Flow | |||||
| Free Cash Flow | -81.84M | -81.51M | -164.58M | -121.43M | -139.39M |
| Operating Cash Flow | -81.53M | -79.67M | -162.76M | -109.33M | -138.03M |
| Investing Cash Flow | -734.00K | -1.58M | -442.00K | -12.32M | -1.36M |
| Financing Cash Flow | 45.18M | 61.52M | 242.10M | 8.19M | 127.03M |
Immunicum AB Technical Analysis
Neutral
5.77
Price Trends
4.66
Negative
5.09
Negative
6.21
Negative
Market Momentum
-0.02
Negative
50.12
Neutral
37.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IMMU, the sentiment is Neutral. The current price of 5.77 is above the 20-day moving average (MA) of 4.25, above the 50-day MA of 4.66, and below the 200-day MA of 6.21, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.12 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:IMMU.
Immunicum AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | kr1.00B | -8.03 | 81.19% | ― | ― | ― | |
52 Neutral | kr293.10M | -3.40 | -25.80% | ― | 127.13% | 56.91% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr144.03M | 121.99 | -16.90% | ― | 4.64% | ― | |
45 Neutral | kr271.88M | -1.89 | -16.51% | ― | ― | 31.37% | |
42 Neutral | kr27.43M | -0.24 | -186.13% | ― | ― | 0.30% | |
40 Underperform | kr86.73M | -2.27 | -4.90% | ― | 41.83% | -183.68% |
* Healthcare Sector Average
SE:IMMU
Immunicum AB
4.44
-0.95
-17.63%
SE:MAGLE
Magle Chemoswed Holding AB
4.20
-22.40
-84.21%
SE:XBRANE
Xbrane Biopharma AB
6.99
-15.85
-69.39%
SE:IVACC
Intervacc AB
0.86
-0.08
-8.32%
SE:GUARD
Guard Therapeutics International AB
1.36
-11.79
-89.66%
SE:CANTA
Cantargia AB
4.03
2.78
222.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.